Skip to content

Guar Gum Trial in Type 2 Diabetes Patients

Influence of Soluble Dietary Fiber (Partially Hydrolyzed Guar Gum) on Gut Microbiota in patients with Type 2 Diabetes: A Multicenter, Double-Blind, Placebo-Controlled Trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1051240099
Enrollment
108
Registered
2024-07-24
Start date
2024-12-21
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Intervention Group: Dissolve one packet of guar gum hydrolysate (5.15g, containing 5.0g of guar gum hydrolysate and 0.15g of cellulose) in a drink and consume twice daily before meals. Control Group:

Sponsors

Nakashima Koya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients who have provided written consent of their own free will. 2) Males and females aged 20 years or older and under 80 years at the time of consent. 3) Patients diagnosed with type 2 diabetes. 4) Patients with an HbA1c value of 6.5% or higher within 37 days prior to obtaining consent.

Exclusion criteria

Exclusion criteria: 1) Patients with cognitive impairment who cannot fully understand the purpose or methods of this study. 2) Patients who started diabetes medications within 5 months prior to obtaining consent. 3) Patients who had a change in diabetes medications within 2 months prior to obtaining consent. 4) Patients undergoing insulin therapy. 5) Patients scheduled for surgery during the study period. 6) Patients with hypersensitivity to dietary fiber or a history of adverse reactions to dietary fiber intake. 7) Patients with severe gastrointestinal symptoms or gastrointestinal diseases. 8) Women who are breastfeeding, pregnant, or have a positive pregnancy test, and women who wish to become pregnant during the study period. 9) Other patients deemed unsuitable as study subjects by the principal or sub-investigator.

Design outcomes

Primary

MeasureTime frame
The gut microbiota at the , particularly the proportion of Akkermansia in the total gut bacteria.

Secondary

MeasureTime frame
Gut microbiota 90 days after consuming the test food HbA1c 90 days after consuming the test food Short-chain fatty acids 90 days after consuming the test food

Contacts

Public ContactKoya Nakashima

Director

nakashimako@k9.dion.ne.jp+81-92-954-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026